Tag Archive for: chemoproteomic

Versant Ventures-backed Belharra Therapeutics launched Wednesday with $130 million in total financing to advance its novel chemoproteomics platform. 

Bayer subsidiary Vividion Therapeutics and precision oncology company Tavros Therapeutics entered into a five-year collaboration agreement, valued at up to $930 million, to discover and develop four novel oncology targets.